EE05517B1 - C hepatiidi inhibiitor tripeptiidid - Google Patents

C hepatiidi inhibiitor tripeptiidid

Info

Publication number
EE05517B1
EE05517B1 EEP200100081A EEP200100081A EE05517B1 EE 05517 B1 EE05517 B1 EE 05517B1 EE P200100081 A EEP200100081 A EE P200100081A EE P200100081 A EEP200100081 A EE P200100081A EE 05517 B1 EE05517 B1 EE 05517B1
Authority
EE
Estonia
Prior art keywords
hepatitis
inhibitor tripeptides
tripeptides
inhibitor
Prior art date
Application number
EEP200100081A
Other languages
English (en)
Estonian (et)
Inventor
Montse@Llinas@Brunet
Murray@D@@Bailey
Dale@Cameron
Anne@Marie@Faucher
Elise@Ghiro
Nathalie@Goudreau
Teddy@Halmos
Marc@Andr�@Poupart
Jean@Rancourt
Youla@S@@Tsantrizos
Dominik@M@@Wernic
Bruno@Simoneau
Original Assignee
Boehringer@Ingelheim@@Canada)@Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer@Ingelheim@@Canada)@Ltd filed Critical Boehringer@Ingelheim@@Canada)@Ltd
Publication of EE200100081A publication Critical patent/EE200100081A/xx
Publication of EE05517B1 publication Critical patent/EE05517B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/02—Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C12P41/005—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of carboxylic acid groups in the enantiomers or the inverse reaction

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200100081A 1998-08-10 1999-08-09 C hepatiidi inhibiitor tripeptiidid EE05517B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9593198P 1998-08-10 1998-08-10
US13238699P 1999-05-04 1999-05-04
PCT/CA1999/000736 WO2000009543A2 (en) 1998-08-10 1999-08-09 Hepatitis c inhibitor tri-peptides

Publications (2)

Publication Number Publication Date
EE200100081A EE200100081A (et) 2002-08-15
EE05517B1 true EE05517B1 (et) 2012-02-15

Family

ID=26790767

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100081A EE05517B1 (et) 1998-08-10 1999-08-09 C hepatiidi inhibiitor tripeptiidid

Country Status (43)

Country Link
US (11) US6323180B1 (forum.php)
EP (2) EP1105413B1 (forum.php)
JP (2) JP4485685B2 (forum.php)
KR (2) KR100631439B1 (forum.php)
CN (2) CN100339389C (forum.php)
AR (3) AR020880A1 (forum.php)
AT (1) ATE430158T1 (forum.php)
AU (1) AU769738B2 (forum.php)
BG (1) BG65738B1 (forum.php)
BR (2) BRPI9913646B8 (forum.php)
CA (2) CA2338946C (forum.php)
CO (1) CO5261542A1 (forum.php)
CY (2) CY1109291T1 (forum.php)
CZ (2) CZ301268B6 (forum.php)
DE (1) DE69940817D1 (forum.php)
DK (2) DK2028186T3 (forum.php)
EA (1) EA003906B1 (forum.php)
EE (1) EE05517B1 (forum.php)
ES (2) ES2405930T3 (forum.php)
HK (1) HK1040085B (forum.php)
HR (1) HRP20010102B1 (forum.php)
HU (2) HU229262B1 (forum.php)
ID (1) ID27839A (forum.php)
IL (3) IL141012A0 (forum.php)
IN (3) IN211493B (forum.php)
ME (1) ME00381B (forum.php)
MX (2) MX257413B (forum.php)
MY (1) MY127538A (forum.php)
NO (2) NO328952B1 (forum.php)
NZ (1) NZ510396A (forum.php)
PE (1) PE20000949A1 (forum.php)
PH (1) PH11999002002B1 (forum.php)
PL (1) PL204850B1 (forum.php)
PT (2) PT1105413E (forum.php)
RS (3) RS53562B1 (forum.php)
SA (1) SA99200617B1 (forum.php)
SI (2) SI2028186T1 (forum.php)
SK (2) SK286994B6 (forum.php)
TR (2) TR200200129T2 (forum.php)
TW (1) TWI250165B (forum.php)
UA (1) UA75026C2 (forum.php)
WO (1) WO2000009543A2 (forum.php)
ZA (1) ZA200100971B (forum.php)

Families Citing this family (423)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4080541B2 (ja) 1996-10-18 2008-04-23 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼの阻害因子
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
ES2177475T1 (es) * 1999-06-25 2002-12-16 Basf Ag Genes de corynebacterium glutamicum que codifican proteinas de una ruta metabolica.
KR20030036152A (ko) 2000-04-05 2003-05-09 쉐링 코포레이션 Ｎ-사이클릭 ｐ2 잔기를 포함하는 ｃ형 간염 바이러스의매크로사이클릭 ｎｓ3-세린 프로테아제 억제제
CN1935833A (zh) 2000-04-19 2007-03-28 先灵公司 含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3－丝氨酸蛋白酶抑制剂
AU2001259511A1 (en) * 2000-05-05 2001-11-20 Smith Kline Beecham Corporation Novel anti-infectives
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
AR034127A1 (es) * 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
CZ2003195A3 (cs) 2000-07-21 2003-04-16 Schering Corporation Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostředek
US7012066B2 (en) 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
CA2429359A1 (en) * 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
ATE430166T1 (de) 2000-12-12 2009-05-15 Schering Corp Diarylrest entfassende peptide als inhibitoren des ns-3 serinproteases von hepatitis c virus
ATE526339T1 (de) 2001-01-22 2011-10-15 Merck Sharp & Dohme Nukleosidderivate als inhibitoren der rna- abhängigen viralen rna-polymerase
CA2449504A1 (en) 2001-07-11 2003-01-23 Vertex Pharmaceuticals Incorporated Bridged bicyclic serine protease inhibitors
DE10297210B4 (de) 2001-09-14 2009-01-02 Honda Giken Kogyo K.K. Aufprall absorbierende Frontgrillanordnung für ein Kraftfahrzeug
WO2003035060A1 (en) * 2001-10-24 2003-05-01 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
JP2005511572A (ja) * 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としてのアシルジヒドロピロール誘導体
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
KR20040077767A (ko) 2002-01-23 2004-09-06 쉐링 코포레이션 Ｃ형 간염 바이러스 감염 치료용 ｎｓ3-세린 프로테아제억제제로서의 프롤린 화합물
US7119072B2 (en) * 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
CA2370396A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6642204B2 (en) * 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2369970A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US7091184B2 (en) * 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
RU2004133044A (ru) 2002-04-11 2006-01-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы сериновых протеаз, в частности, протеазы ns3-ns4a hcv
JP4312711B2 (ja) * 2002-05-20 2009-08-12 ブリストル−マイヤーズ スクイブ カンパニー ヘテロ環式スルホンアミドｃ型肝炎ウイルス阻害剤
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2004043339A2 (en) * 2002-05-20 2004-05-27 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
JP4312718B2 (ja) * 2002-05-20 2009-08-12 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
KR100457857B1 (ko) * 2002-05-23 2004-11-18 (주) 비엔씨바이오팜 2-[2-(3-인돌릴)에틸아미노]피리딘 유도체, 그 제조방법및 이를 포함하는 항바이러스용 약학적 조성물
JP2005533817A (ja) 2002-06-28 2005-11-10 イデニクス（ケイマン）リミテツド フラビウィルス科ウィルス感染治療用の修飾２′および３′−ヌクレオシドプロドラッグ
US20040033959A1 (en) * 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
WO2004014852A2 (en) * 2002-08-12 2004-02-19 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of hcv replication
EP1408031A1 (en) * 2002-10-09 2004-04-14 3 D Gene Pharma Pyrolidine derivatives useful in treatment of hepatitis C virus infection
EP1554274B1 (en) * 2002-10-24 2008-12-24 Glaxo Group Limited 1-acyl-pyrrolidine derivatives for the treatment of viral infections
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
EP1601685A1 (en) * 2003-03-05 2005-12-07 Boehringer Ingelheim International GmbH Hepatitis c inhibiting compounds
CA2516018C (en) * 2003-03-05 2011-08-23 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
KR100960802B1 (ko) * 2003-03-08 2010-06-01 주식회사유한양행 씨형 간염바이러스 감염 치료용 엔에스3 프로테아제 억제제
US7148347B2 (en) * 2003-04-10 2006-12-12 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
WO2004094452A2 (en) * 2003-04-16 2004-11-04 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
US6846836B2 (en) 2003-04-18 2005-01-25 Bristol-Myers Squibb Company N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase
US7176208B2 (en) * 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
DE602004023924D1 (en) 2003-04-18 2009-12-17 Enanta Pharm Inc Ease-hemmer
RS51294B (sr) * 2003-05-21 2010-12-31 Boehringer Ingelheim International Gmbh. Inhibitorna jedinjenja za hepatitis c
EP4032897B1 (en) 2003-05-30 2025-01-29 Gilead Pharmasset LLC Modified fluorinated nucleoside analogues
WO2004113365A2 (en) * 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Hepatitis c serine protease tri-peptide inhibitors
US7273851B2 (en) * 2003-06-05 2007-09-25 Enanta Pharmaceuticals, Inc. Tri-peptide hepatitis C serine protease inhibitors
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
DK1658302T3 (da) 2003-07-25 2010-11-22 Idenix Pharmaceuticals Inc Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C
JP4527722B2 (ja) 2003-08-26 2010-08-18 シェーリング コーポレイション Ｃ型肝炎ウイルスの新規のペプチド模倣性ｎｓ３−セリンプロテアーゼインヒビター
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
TWI359147B (en) 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
PE20050431A1 (es) * 2003-09-22 2005-07-19 Boehringer Ingelheim Int Peptidos macrociclicos activos contra el virus de la hepatitis c
AR046166A1 (es) 2003-09-26 2005-11-30 Schering Corp Inhibidores macrociclicos de la serina proteasa ns3 del virus de la hepatitis c
AU2004282148A1 (en) 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incoporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
BRPI0415373A (pt) 2003-10-14 2006-12-12 Intermune Inc ácidos carboxìlicos macrocìclicos e acilsulfonamidas como inibidores de replicação de hcv
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
JP4890254B2 (ja) 2003-10-27 2012-03-07 バーテックス ファーマシューティカルズ インコーポレイテッド Ｈｃｖｎｓ３−ｎｓ４ａプロテアーゼ耐性突然変異体
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
US20050119318A1 (en) * 2003-10-31 2005-06-02 Hudyma Thomas W. Inhibitors of HCV replication
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7253160B2 (en) 2003-11-20 2007-08-07 Schering Corporation Depeptidized inhibitors of hepatitis C virus NS3 protease
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2547770A1 (en) * 2003-12-08 2005-06-23 Fabrice Gallou Removal of ruthenium by-product by supercritical fluid processing
RU2006125441A (ru) 2003-12-15 2008-01-27 Джапан Тобакко Инк. (Jp) Производные циклопропана и их фармацевтическое применение
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
CA2549851C (en) 2004-01-21 2012-09-11 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
AU2005207815B2 (en) 2004-01-30 2011-08-04 Medivir Ab HCV NS-3 serine protease inhibitors
SE0400199D0 (sv) * 2004-01-30 2004-01-30 Medivir Ab HCV Protease inhbitors
CN1938332B (zh) 2004-02-04 2011-10-19 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
CN1922174A (zh) 2004-02-20 2007-02-28 贝林格尔·英格海姆国际有限公司 病毒聚合酶抑制剂
WO2005080399A1 (ja) 2004-02-24 2005-09-01 Japan Tobacco Inc. ４環縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
CN1946690A (zh) * 2004-02-27 2007-04-11 先灵公司 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的含环丁烯二酮基团化合物
ES2349328T3 (es) 2004-02-27 2010-12-30 Schering Corporation Nuevos compuestos como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
RU2006134005A (ru) 2004-02-27 2008-04-10 Шеринг Корпорейшн (US) Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
US7635694B2 (en) 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
TWI314927B (en) 2004-02-27 2009-09-21 Schering Corporatio Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
EP1730165A1 (en) 2004-02-27 2006-12-13 Schering Corporation Inhibitors of hepatitis c virus ns3 protease
US7816326B2 (en) 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
ES2328589T3 (es) 2004-02-27 2009-11-16 Schering Corporation Compuestos de la prolina 3,4(ciclopentil) fusionados como inhibidores de la proteasa serina ns3 del virus de la hepatitis c.
AU2005223767B2 (en) * 2004-03-12 2011-12-01 Vertex Pharmaceuticals Incorporated Processes and intermediates for the preparation of aspartic acetal caspase inhibitors
DE602005019700D1 (de) * 2004-03-15 2010-04-15 Boehringer Ingelheim Int E, die sich für die behandlung von hepatitis-c-virusinfektionen eignen
NZ549697A (en) * 2004-03-30 2009-12-24 Intermune Inc Macrocyclic compounds as inhibitors of viral replication
KR20070011451A (ko) 2004-05-05 2007-01-24 예일 유니버시티 신규의 항바이러스 헬리오크산틴 유사체
US7399749B2 (en) 2004-05-20 2008-07-15 Schering Corporation Substituted prolines as inhibitors of hepatitis C virus NS3 serine protease
JP5156374B2 (ja) * 2004-05-25 2013-03-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 非環式ｈｃｖプロテアーゼインヒビターの調製方法
CA2568379A1 (en) 2004-06-15 2005-12-29 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
AU2005267421B2 (en) 2004-06-24 2010-06-03 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
CA2556669C (en) * 2004-06-28 2012-05-01 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
CA2571984C (en) * 2004-07-16 2012-04-10 Gilead Sciences, Inc. Antiviral compounds
JP4914355B2 (ja) * 2004-07-20 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類似体
UY29016A1 (es) * 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2006020580A2 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
MX2007002371A (es) 2004-08-27 2007-04-23 Schering Corp Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
ES2769377T3 (es) * 2004-09-14 2020-06-25 Gilead Pharmasset Llc Intermedios de D-ribonolactona con sustitución de 2-fluoro-2-alquilo
WO2006030892A1 (ja) * 2004-09-17 2006-03-23 Nippon Shinyaku Co., Ltd. 複素環化合物の製造方法
SG191661A1 (en) 2004-10-01 2013-07-31 Vertex Pharma Hcv ns3-ns4a protease inhibition
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7323447B2 (en) * 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2332963A3 (en) 2005-03-08 2011-11-16 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US7592336B2 (en) * 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7569600B2 (en) 2005-05-13 2009-08-04 Virochem Pharma Inc. Compounds and methods for the treatment of prevention of Flavivirus infections
US20070237818A1 (en) * 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
WO2006130628A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Combination of hcv protease inhibitors with a surfactant
WO2006130686A2 (en) 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors in combination with food
US20060276404A1 (en) * 2005-06-02 2006-12-07 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
AR054778A1 (es) 2005-06-17 2007-07-18 Novartis Ag Uso de sangliferina en hcv
US7608592B2 (en) * 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
CN101242816B (zh) * 2005-06-30 2012-10-31 维罗贝股份有限公司 Hcv抑制剂
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI387603B (zh) * 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
CA2615921C (en) * 2005-07-20 2011-09-13 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs with a quinoline or a thienopyridine moiety
WO2007015824A2 (en) 2005-07-25 2007-02-08 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
PE20070210A1 (es) 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
TWI393723B (zh) 2005-07-29 2013-04-21 Tibotec Pharm Ltd Ｃ型肝炎病毒之大環抑制劑（九）
PL1913015T3 (pl) 2005-07-29 2014-04-30 Janssen R&D Ireland Makrocykliczne inhibitory wirusa zapalenia wątroby typu C
US7666834B2 (en) 2005-07-29 2010-02-23 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis C virus
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
ME01318B (me) 2005-07-29 2013-12-20 Tibotec Pharm Ltd Makrociklički inhibitori virusa hepatitisa C
PE20070343A1 (es) 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
WO2007014920A1 (en) 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
DE602006019741D1 (de) 2005-07-29 2011-03-03 Medivir Ab Makrocyclische inhibitoren des hepatitis-c-virus
CA2615896C (en) * 2005-08-01 2012-11-13 Merck & Co., Inc. Macrocyclic peptides as hcv ns3 protease inhibitors
MX2008001528A (es) 2005-08-02 2008-04-04 Vertex Pharma Inhibidores de serina proteasas.
US7632821B2 (en) 2005-08-09 2009-12-15 Merck & Co., Inc. Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection
US8076365B2 (en) 2005-08-12 2011-12-13 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
ES2344156T3 (es) 2005-08-19 2010-08-19 Vertex Pharmaceuticals Incorporated Procedimientos e intermedios.
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US7951773B2 (en) 2005-09-09 2011-05-31 Boehringer Ingelheim International Gmbh Ring-closing metathesis process for the preparation of macrocyclic peptides
KR20080056295A (ko) 2005-10-11 2008-06-20 인터뮨, 인크. Ｃ형 간염 바이러스 복제를 억제하기 위한 화합물 및 방법
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
EP2392588A3 (en) 2005-11-11 2012-03-07 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
AU2006330924B2 (en) * 2005-12-21 2012-03-15 Abbvie Inc. Anti-viral compounds
US7915411B2 (en) 2005-12-21 2011-03-29 Abbott Laboratories Anti-viral compounds
EP2345652A1 (en) 2005-12-21 2011-07-20 Abbott Laboratories Antiviral compounds
RU2467007C2 (ru) 2005-12-21 2012-11-20 Эбботт Лэборетриз Производные [1,8]нафтиридина, полезные в качестве ингибиторов репликации вируса hcv
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
JP5436864B2 (ja) 2006-02-27 2014-03-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｖｘ−９５０を含む共結晶体およびそれを含む医薬組成物
CA2645072A1 (en) 2006-03-08 2007-09-13 Achillion Pharmaceuticals, Inc. Substituted aminothiazole derivatives with anti-hcv activity
WO2007109080A2 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
BRPI0710878A2 (pt) 2006-04-11 2015-03-31 Novartis Ag Compostos orgânicos e seus usos
GB0609492D0 (en) * 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
RU2419626C2 (ru) 2006-05-23 2011-05-27 Айрм Ллк Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы
US9526769B2 (en) 2006-06-06 2016-12-27 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US20080187516A1 (en) * 2006-06-06 2008-08-07 Ying Sun Acyclic oximyl hepatitis c protease inhibitors
US7728148B2 (en) * 2006-06-06 2010-06-01 Enanta Pharmaceuticals, Inc. Acyclic oximyl hepatitis C protease inhibitors
US8268776B2 (en) 2006-06-06 2012-09-18 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
GB0612423D0 (en) * 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
PE20080992A1 (es) * 2006-06-26 2008-08-06 Enanta Pharm Inc Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US7635683B2 (en) * 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
US7718612B2 (en) * 2007-08-02 2010-05-18 Enanta Pharmaceuticals, Inc. Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
US20090035267A1 (en) * 2007-07-31 2009-02-05 Moore Joel D Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
US7605126B2 (en) * 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
US7582605B2 (en) * 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
US20090098085A1 (en) * 2006-08-11 2009-04-16 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
WO2008022006A2 (en) * 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis c virus protease inhibitors
US20080038225A1 (en) * 2006-08-11 2008-02-14 Ying Sun Triazolyl acyclic hepatitis c serine protease inhibitors
US7687459B2 (en) * 2006-08-11 2010-03-30 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis C virus protease inhibitors
BRPI0716060A2 (pt) 2006-08-17 2013-09-17 Boehringer Ingelheim Int inibidores de polimerase viral.
KR20090057035A (ko) * 2006-08-21 2009-06-03 유나이티드 세러퓨틱스 코오포레이션 바이러스 감염의 치료를 위한 병용 요법
CA2667146C (en) * 2006-10-24 2016-01-19 Merck & Co., Inc. Hcv ns3 protease inhibitors
JP2010507656A (ja) * 2006-10-24 2010-03-11 メルク エンド カムパニー インコーポレーテッド Ｈｃｖｎｓ３プロテアーゼ阻害剤
CA2667266C (en) * 2006-10-24 2015-11-24 Merck & Co., Inc. Hcv ns3 protease inhibitors
CN101568346B (zh) * 2006-10-27 2015-11-25 默沙东公司 Hcv ns3蛋白酶抑制剂
KR101615500B1 (ko) * 2006-10-27 2016-04-27 머크 샤프 앤드 돔 코포레이션 Ｈｃｖ ｎｓ3 프로테아제 억제제
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US20080108632A1 (en) * 2006-11-02 2008-05-08 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2007321677B2 (en) 2006-11-15 2013-04-11 Vertex Pharmaceuticals (Canada) Incorporated Thiophene analogues for the treatment or prevention of flavivirus infections
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CL2007003299A1 (es) 2006-11-17 2008-08-22 Tibotec Pharm Ltd Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
EP2099430A2 (en) 2006-12-07 2009-09-16 Schering Corporation Ph sensitive matrix formulation
CA2672737A1 (en) * 2006-12-20 2008-11-06 Abbott Laboratories Anti-viral compounds
WO2008075103A1 (en) * 2006-12-20 2008-06-26 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Antiviral indoles
GB0625345D0 (en) * 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625349D0 (en) * 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008074035A1 (en) * 2006-12-27 2008-06-19 Abbott Laboratories Hcv protease inhibitors and uses thereof
US20080207528A1 (en) * 2007-02-01 2008-08-28 Syaulan Yang Hcv protease inhibitors
EP2134717A2 (en) 2007-02-27 2009-12-23 Vertex Pharmceuticals Incorporated Inhibitors of serine proteases
PT2114924E (pt) 2007-02-27 2012-04-03 Vertex Pharma Co-cristais e composições farmacêuticas que compreendem os mesmos
CA2696053A1 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
CN101679240A (zh) * 2007-03-23 2010-03-24 先灵公司 Hcv ns3蛋白酶的p1-非可差向异构化酮酰胺抑制剂
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20080267917A1 (en) * 2007-04-26 2008-10-30 Deqiang Niu N-functionalized amides as hepatitis c serine protease inhibitors
US20080292587A1 (en) * 2007-04-26 2008-11-27 Ying Sun Oximyl dipeptide hepatitis c protease inhibitors
US20080317712A1 (en) * 2007-04-26 2008-12-25 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl tripeptide hepatitis c serine protease inhibitors
US7910587B2 (en) * 2007-04-26 2011-03-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl dipeptide hepatitis C virus inhibitors
US8377872B2 (en) 2007-04-26 2013-02-19 Enanta Pharmaceuticals, Inc. Cyclic P3 tripeptide hepatitis C serine protease inhibitors
AP2009005053A0 (en) * 2007-05-03 2009-12-31 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
MX2009011930A (es) 2007-05-04 2009-11-18 Vertex Pharma Terapia de combinacion para el tratamiento de infeccion de virus de hepatitis c.
KR20120011093A (ko) * 2007-05-09 2012-02-06 화이자 인코포레이티드 치환된 헤테로사이클릭 유도체 및 조성물 및 항균제로서의 이의 약학적 용도
EA200971041A1 (ru) 2007-05-10 2010-08-30 Интермьюн, Инк. Новые пептидные ингибиторы репликации вируса гепатита с
GB0709791D0 (en) * 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
BRPI0813733A2 (pt) * 2007-06-29 2019-11-05 Gilead Sciences Inc composto com atividade inibidora de hcv, sua composição farmacêutica e seu uso.
WO2009005676A2 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
EP2178886A1 (en) * 2007-07-17 2010-04-28 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic indole derivatives for the treatment of hepatitis c infections
CA2699891C (en) * 2007-07-19 2013-10-22 Nigel Liverton Macrocyclic compounds as antiviral agents
CA2693997C (en) 2007-08-03 2013-01-15 Pierre L. Beaulieu Viral polymerase inhibitors
EP2185546B1 (en) 2007-08-30 2011-10-26 Vertex Pharmceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
GB0718575D0 (en) 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
US20090111757A1 (en) * 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
CA2705803A1 (en) 2007-11-14 2009-05-22 Enanta Pharmaceuticals, Inc. Macrocyclic tetrazolyl hepatitis c serine protease inhibitors
US8030307B2 (en) * 2007-11-29 2011-10-04 Enanta Pharmaceuticals, Inc. Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease
WO2009070692A1 (en) * 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors
US8361958B2 (en) * 2007-12-05 2013-01-29 Enanta Pharmaceuticals, Inc. Oximyl HCV serine protease inhibitors
CA2708150A1 (en) * 2007-12-05 2009-06-18 Enanta Pharmaceuticals, Inc. Fluorinated tripeptide hcv serine protease inhibitors
US8193346B2 (en) 2007-12-06 2012-06-05 Enanta Pharmaceuticals, Inc. Process for making macrocyclic oximyl hepatitis C protease inhibitors
WO2009079353A1 (en) 2007-12-14 2009-06-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic hcv serine protease inhibitors
EP2234977A4 (en) 2007-12-19 2011-04-13 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
CA2712940A1 (en) * 2008-01-24 2009-07-30 Enanta Pharmaceuticals, Inc. Heteroaryl-containing tripeptide hcv serine protease inhibitors
MX2010008109A (es) * 2008-01-24 2010-09-22 Enanta Pharm Inc Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv).
AU2009210789B2 (en) 2008-02-04 2014-01-30 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
WO2009100225A1 (en) 2008-02-07 2009-08-13 Virobay, Inc. Inhibitors of cathepsin b
WO2009108507A1 (en) 2008-02-25 2009-09-03 Merck & Co., Inc. Therapeutic compounds
EP2268619A4 (en) * 2008-03-20 2012-04-04 Enanta Pharm Inc FLUORINATED MACROCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
SG175692A1 (en) 2008-04-15 2011-11-28 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2720850A1 (en) * 2008-04-28 2009-11-05 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
WO2009134987A1 (en) * 2008-04-30 2009-11-05 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors
US20090285774A1 (en) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN101580535B (zh) * 2008-05-16 2012-10-03 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2300491B1 (en) 2008-05-29 2016-01-06 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2476690A1 (en) 2008-07-02 2012-07-18 IDENIX Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
PT2540350E (pt) * 2008-07-22 2014-08-27 Merck Sharp & Dohme Combinações de um composto de quinoxalina macrocílico o qual é um inibidor da protease ns3 do hcv com outros agentes do hcv
CA2730517A1 (en) 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
US8207341B2 (en) * 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
EP2687526A1 (en) * 2008-09-16 2014-01-22 Boehringer Ingelheim International Gmbh Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor
UA103496C2 (uk) * 2008-09-17 2013-10-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Комбінація інгібітора протеази ns3 hcv з інтерфероном і рибавірином
CA2736472A1 (en) 2008-09-26 2010-04-01 F. Hoffmann-La Roche Ag Pyrine or pyrazine derivatives for treating hcv
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2341924A4 (en) 2008-10-02 2013-01-23 David Gladstone Inst METHOD FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS
EA201170441A1 (ru) * 2008-10-15 2012-05-30 Интермьюн, Инк. Терапевтические противовирусные пептиды
CA2741325A1 (en) 2008-10-30 2010-05-06 F. Hoffmann-La Roche Ag Heterocyclic antiviral arylpyridone derivatives
BRPI0921070A2 (pt) * 2008-11-21 2019-09-24 Boehringer Ingelheim Int composição farmacêutica líquida de um inibidor de hcv potente para administração oral
WO2010065668A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
PE20150939A1 (es) 2008-12-03 2015-07-19 Presidio Pharmaceuticals Inc Inhibidores de la proteina no estructural 5a del virus de la hepatitis c
US20100272674A1 (en) * 2008-12-04 2010-10-28 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010080389A1 (en) 2008-12-19 2010-07-15 Gilead Sciences, Inc. Hcv ns3 protease inhibitors
BRPI0924121A2 (pt) 2008-12-22 2019-09-24 Hoffmann La Roche compostos antivirais heterocíclicos
TW201036612A (en) 2008-12-22 2010-10-16 Gilead Sciences Inc Antiviral compounds
JP5713919B2 (ja) 2008-12-23 2015-05-07 ギリアド ファーマセット エルエルシー ヌクレオシドホスホラミデート
PA8855701A1 (es) 2008-12-23 2010-07-27 Análogos de nucleósidos
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
CA2750227A1 (en) 2009-01-07 2010-07-15 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
WO2010082050A1 (en) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
WO2010101967A2 (en) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole hcv polymerase inhibitors
CN102341382A (zh) 2009-03-06 2012-02-01 弗·哈夫曼-拉罗切有限公司 抗病毒的杂环化合物
JP2012520884A (ja) 2009-03-18 2012-09-10 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー フラビウイルス科ウイルス感染症を治療する方法および組成物
JP5735482B2 (ja) 2009-03-27 2015-06-17 プレシディオ ファーマシューティカルズ インコーポレイテッド 縮合環のｃ型肝炎阻害剤
WO2010118009A1 (en) * 2009-04-06 2010-10-14 Ptc Therapeutics, Inc. Hcv inhibitor and therapeutic agent combinations
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
SG175774A1 (en) 2009-04-25 2011-12-29 Hoffmann La Roche Heterocyclic antiviral compounds
CN102458444A (zh) 2009-05-13 2012-05-16 英安塔制药有限公司 用作丙型肝炎病毒抑制剂的大环化合物
TWI598358B (zh) * 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
AR077004A1 (es) * 2009-06-09 2011-07-27 Hoffmann La Roche Compuestos heterociclicos antivirales
AU2010264802A1 (en) 2009-06-24 2012-01-19 F. Hoffmann-La Roche Ag Heterocyclic antiviral compound
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
WO2011003063A2 (en) * 2009-07-02 2011-01-06 Dr. Reddy's Laboratories Ltd. Enzymes and methods for resolving amino vinyl cyclopropane carboxylic acid derivatives
CA2767692C (en) 2009-07-07 2017-03-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition for a hepatitis c viral protease inhibitor
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
CA2769652A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
WO2011019066A1 (ja) * 2009-08-10 2011-02-17 住友化学株式会社 光学活性な１－アミノ－２－ビニルシクロプロパンカルボン酸エステルの製造方法
US8324417B2 (en) 2009-08-19 2012-12-04 Virobay, Inc. Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
HRP20161025T1 (hr) * 2009-09-15 2016-11-04 Taigen Biotechnology Co., Ltd. Inhibitori proteaze hcv-a
EA201290128A1 (ru) * 2009-09-28 2013-01-30 Интермьюн, Инк. Новые макроциклические ингибиторы репликации вируса гепатита с
US9193740B2 (en) * 2009-10-19 2015-11-24 Enanta Pharmaceuticals, Inc. Bismacrocyclic compounds as hepatitis C virus inhibitors
AU2010313497B2 (en) 2009-10-30 2013-08-01 Boehringer Ingelheim International Gmbh Dosage regimens for HCV combination therapy comprising BI201335, interferon alpha and ribavirin
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
CA2781614A1 (en) 2009-11-25 2011-06-09 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
TW201136942A (en) 2009-12-18 2011-11-01 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
CN102883718A (zh) 2009-12-24 2013-01-16 顶点制药公司 用于治疗或预防黄病毒感染的类似物
US20110178107A1 (en) * 2010-01-20 2011-07-21 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
BR112012018897A2 (pt) 2010-01-27 2017-10-03 Ab Pharma Ltd Compostos poli-heterocíclicos altamente potentes como inibidores de hcv
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor
MX2012010919A (es) 2010-03-24 2013-02-01 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones por flavivirus.
WO2011119858A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
JP2013522375A (ja) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染を処置または予防するためのアナログ
TW201141857A (en) 2010-03-24 2011-12-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
TW201139457A (en) 2010-03-31 2011-11-16 Pharmasset Inc Stereoselective synthesis of phosphorus containing actives
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
BR112012024661A2 (pt) 2010-04-01 2015-09-15 Centre Nat Rech Scient composto, composição farmacêutica e método de tratamento de um hospedeiro infectado com vírus de hepatite c
WO2011149856A1 (en) 2010-05-24 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
EP2582717A2 (en) 2010-06-15 2013-04-24 Vertex Pharmaceuticals Incorporated Hcv ns5b polymerase mutants
MX2012014918A (es) 2010-06-28 2013-04-08 Vertex Pharma Compuestos y metodos para tratamiento o prevencion de infecciones por flavivirus.
EP2585448A1 (en) 2010-06-28 2013-05-01 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
MX2013001869A (es) 2010-08-17 2013-06-28 Vertex Pharma Compuestos y metodos para el tratamiento o prevencion de infecciones virales por flaviviridae.
SG188618A1 (en) 2010-09-21 2013-04-30 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
BR112013007423A2 (pt) * 2010-09-30 2016-07-12 Boehringer Ingelheim Int terapia combinada no que diz respeito ao tratamento da infecção por hcv
BR112013008510A2 (pt) 2010-10-08 2016-07-05 Novartis Ag vitamina e formulações de inibidores de sulfamida ns3
EP3042910B1 (en) 2010-11-30 2019-01-09 Gilead Pharmasset LLC 2'-spiro-nucleosides for use in the therapy of hepatitis c
MX2013006951A (es) * 2010-12-16 2013-10-03 Abbvie Inc Compuestos antivirales.
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
EP2658859A4 (en) 2010-12-30 2014-07-30 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
WO2012154321A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2857705A1 (en) 2011-06-16 2012-12-20 AB Pharma Ltd. Macrocyclic heterocyclic compounds for inhibiting hepatitis c virus and preparation and use thereof
EP2725012A1 (en) 2011-06-21 2014-04-30 Mitsubishi Gas Chemical Company, Inc. 1-amino-2-vinyl cyclopropane carboxylic acid amide, salt of same, and method for producing same
WO2012175581A1 (en) 2011-06-24 2012-12-27 F. Hoffmann-La Roche Ag Antiviral compounds
CN102807607B (zh) * 2011-07-22 2013-10-23 爱博新药研发(上海)有限公司 抑制丙肝病毒的稠环杂环类化合物、其中间体及其应用
WO2013016490A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Thiophene compounds
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
DE202012012998U1 (de) 2011-08-31 2014-06-13 Daniel Elias Bioaktive, regenerative Mischung zur Herstellung eines Ergänzungsnahrungsmittels
CA2847892A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013039920A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
KR101621181B1 (ko) 2011-10-10 2016-05-13 에프. 호프만-라 로슈 아게 항바이러스성 화합물
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
GB2506085A (en) 2011-10-21 2014-03-19 Abbvie Inc Combination treatment (eg with ABT-072 or ABT-333) of DAAS for use in treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
PT107894A (pt) 2011-10-21 2014-10-31 Abbvie Inc Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EP2780026B1 (en) 2011-11-15 2019-10-23 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
ES3018133T3 (en) 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
WO2013086133A1 (en) 2011-12-06 2013-06-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating viral diseases
KR20140104030A (ko) 2011-12-16 2014-08-27 에프. 호프만-라 로슈 아게 Hcv ns5a의 억제제
CN104011060A (zh) 2011-12-20 2014-08-27 弗·哈夫曼-拉罗切有限公司 作为hcv rna复制抑制剂的4‘-叠氮基,3’-氟取代的核苷衍生物
MY171577A (en) 2011-12-20 2019-10-21 Hoffmann La Roche 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
US20140356325A1 (en) 2012-01-12 2014-12-04 Ligand Pharmaceuticals Incorporated Novel 2'-c-methyl nucleoside derivative compounds
PE20141817A1 (es) 2012-01-12 2014-12-17 Boehringer Ingelheim Int Formulaciones farmaceuticas estabilizadas de un potente inhibidor de hcv
WO2013133927A1 (en) 2012-02-13 2013-09-12 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate]
CA2857262A1 (en) 2012-02-24 2013-08-29 F. Hoffmann-La Roche Ag Antiviral compounds
JP2015509980A (ja) 2012-03-14 2015-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
WO2013147750A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
WO2013147749A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient subgenotype populations
JP2015512900A (ja) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
JP6165848B2 (ja) 2012-05-22 2017-07-19 イデニク ファーマシューティカルズ エルエルシー 肝疾患のためのｄ−アミノ酸化合物
US20140010783A1 (en) 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
MX353422B (es) 2012-10-08 2018-01-12 Idenix Pharmaceuticals Llc Análogos de 2'-cloronucleósido para infección por vhc.
RS55592B1 (sr) 2012-10-19 2017-06-30 Bristol Myers Squibb Co 9-metil supstituisani heksadekahidrociklopropa(e)pirolo(1,2-a)(1,4)diazaciklopentadecinil karbamat derivati kao nestrukturalni 3 (ns3) proteazni inhibitori za lečenje infekcijavirusom hepatitisa c
US20140112886A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
EP2909222B1 (en) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC 2',4'-bridged nucleosides for hcv infection
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014078436A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
CN103804208B (zh) * 2012-11-14 2016-06-08 重庆博腾制药科技股份有限公司 一种丙肝药物中间体的制备方法
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
BR112015017414A2 (pt) 2013-01-23 2017-07-11 Hoffmann La Roche derivados de triazol antivirais
WO2014121418A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121417A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
TW201526899A (zh) 2013-02-28 2015-07-16 Alios Biopharma Inc 醫藥組成物
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
EP2964637B1 (en) 2013-03-05 2017-04-12 F. Hoffmann-La Roche AG Antiviral compounds
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
SG11201507469RA (en) 2013-03-14 2015-10-29 Achillion Pharmaceuticals Inc Processes for producing sovaprevir
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
SG11201509427RA (en) 2013-05-16 2015-12-30 Riboscience Llc 4'-azido, 3'-deoxy-3'-fluoro substituted nucleoside derivatives
CA2912682C (en) 2013-05-16 2021-07-06 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
KR102239196B1 (ko) 2013-08-27 2021-04-12 길리애드 파마셋 엘엘씨 2종의 항바이러스 화합물의 조합 제제
EP3046924A1 (en) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
US20160271162A1 (en) 2013-11-01 2016-09-22 Idenix Pharmacueticals, Llc D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
US20170198005A1 (en) 2013-11-27 2017-07-13 Idenix Pharmaceuticals Llc 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
US9717797B2 (en) 2013-12-05 2017-08-01 International Business Machines Corporation Polycarbonates bearing aromatic N-heterocycles for drug delivery
WO2015095419A1 (en) 2013-12-18 2015-06-25 Idenix Pharmaceuticals, Inc. 4'-or nucleosides for the treatment of hcv
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
EP3113763A1 (en) 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
EP3684374B1 (en) 2017-09-21 2025-07-30 Riboscience LLC 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
EP3891508A1 (en) 2018-12-04 2021-10-13 Bristol-Myers Squibb Company Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0475255A3 (en) * 1990-09-12 1993-04-14 F. Hoffmann-La Roche Ag Process for the preparation of optically pure (s)-alpha-((tert-butylsulfonyl)methyl)hydro cinnamic acid
JPH05155827A (ja) * 1991-12-09 1993-06-22 Banyu Pharmaceut Co Ltd ｃｉｓ−２−アミノシクロプロパンカルボン酸誘導体の製造法
IT1272179B (it) 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
CN1141591A (zh) * 1994-02-23 1997-01-29 布·安格莱荻公司分子生物学研究所 体外再生丙型肝炎病毒(hcv)ns3蛋白酶的解蛋白活性的方法
GB9517022D0 (en) 1995-08-19 1995-10-25 Glaxo Group Ltd Medicaments
IT1277914B1 (it) * 1995-08-22 1997-11-12 Angeletti P Ist Richerche Bio Procedimento per produrre - in forma pura e in quantita' elevate - polipeptidi con l'attivita' proteolitica della proteasi ns3 di hcv, e
CA2165996C (en) * 1995-12-22 2002-01-29 Murray Douglas Bailey Stereoselective preparation of 2-substituted succinic derivatives
DE19600034C2 (de) 1996-01-02 2003-12-24 Degussa 1,1,2-Trisubstituierte Cyclopropanverbindungen, Verfahren zu deren Herstellung und Dihydroxyethyl-substituierte 1-Amino-cyclopropan-1-carbonsäure
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
JP4080541B2 (ja) 1996-10-18 2008-04-23 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼの阻害因子
WO1998053814A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
JP4354632B2 (ja) 1997-08-11 2009-10-28 ベーリンガー インゲルハイム （カナダ） リミテッド Ｃ型肝炎抑制剤ペプチド
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
SE9704543D0 (sv) * 1997-12-05 1997-12-05 Astra Ab New compounds
US6455571B1 (en) * 1998-04-23 2002-09-24 Abbott Laboratories Inhibitors of neuraminidases
DE19835120C1 (de) * 1998-08-04 1999-10-21 Westfalia Separator Ag Verfahren und Vorrichtung zum Einstellen des Flüssigkeitsgehalts des aus einer selbstentleerenden Schleudertrommel eines Separators ausgetragenen Feststoffes
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6642204B2 (en) * 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7091184B2 (en) * 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2516018C (en) * 2003-03-05 2011-08-23 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
EP1601685A1 (en) * 2003-03-05 2005-12-07 Boehringer Ingelheim International GmbH Hepatitis c inhibiting compounds

Also Published As

Publication number Publication date
USRE41356E1 (en) 2010-05-25
IN2001MU00127A (forum.php) 2005-03-04
EA003906B1 (ru) 2003-10-30
US6323180B1 (en) 2001-11-27
CN1323316A (zh) 2001-11-21
HUP0105144A3 (en) 2002-11-28
BRPI9913646B8 (pt) 2021-05-25
US20020037998A1 (en) 2002-03-28
HRP20010102B1 (en) 2010-07-31
US20020016442A1 (en) 2002-02-07
AR069583A2 (es) 2010-02-03
UA75026C2 (en) 2006-03-15
JP4485685B2 (ja) 2010-06-23
CZ2001516A3 (cs) 2001-08-15
SI1105413T1 (sl) 2009-10-31
KR100631439B1 (ko) 2006-10-09
HU230701B1 (hu) 2017-10-30
USRE42164E1 (en) 2011-02-22
AR020880A1 (es) 2002-06-05
HU229262B1 (en) 2013-10-28
ME00381B (me) 2011-10-10
USRE41894E1 (en) 2010-10-26
AR073428A2 (es) 2010-11-03
MX257413B (es) 2008-05-27
CZ302766B6 (cs) 2011-10-26
MX261584B (es) 2008-10-22
DE69940817D1 (en) 2009-06-10
CN100339389C (zh) 2007-09-26
PH11999002002B1 (en) 2007-10-19
ATE430158T1 (de) 2009-05-15
IN211493B (forum.php) 2008-01-25
CN101143892B (zh) 2010-12-08
RS50798B (sr) 2010-08-31
IL141012A (en) 2009-09-01
ZA200100971B (en) 2002-06-26
NO336663B1 (no) 2015-10-12
CA2445938A1 (en) 2000-02-24
US6329417B1 (en) 2001-12-11
US6534523B1 (en) 2003-03-18
CZ301268B6 (cs) 2009-12-30
BR9913646A (pt) 2001-06-05
PT1105413E (pt) 2009-06-30
CY1113935T1 (el) 2016-07-27
MEP58508A (en) 2011-05-10
TWI250165B (en) 2006-03-01
IL196545A (en) 2012-06-28
BG65738B1 (bg) 2009-09-30
SI2028186T1 (sl) 2013-06-28
ES2326707T3 (es) 2009-10-16
BR9917805B1 (pt) 2014-06-17
RS20090459A (en) 2010-06-30
BR9913646B1 (pt) 2014-12-02
NO20010683L (no) 2001-04-02
DK2028186T3 (da) 2013-03-25
RS53562B1 (sr) 2015-02-27
PT2028186E (pt) 2013-03-27
HUP0105144A2 (hu) 2002-04-29
TR200100432T2 (tr) 2001-09-21
CO5261542A1 (es) 2003-03-31
NO328952B1 (no) 2010-06-28
EP2028186A2 (en) 2009-02-25
USRE40525E1 (en) 2008-09-30
SK288068B6 (sk) 2013-05-03
TR200200129T2 (tr) 2002-06-21
SK286994B6 (sk) 2009-09-07
AU769738B2 (en) 2004-02-05
SA99200617B1 (ar) 2006-06-24
YU9401A (sh) 2003-02-28
BG105232A (en) 2001-11-30
MY127538A (en) 2006-12-29
CA2445938C (en) 2012-10-30
US6410531B1 (en) 2002-06-25
NO20010683D0 (no) 2001-02-09
HK1113164A1 (en) 2008-09-26
PL346626A1 (en) 2002-02-25
NO20100004L (no) 2001-04-02
IN2007MU00706A (forum.php) 2007-07-20
HK1040085A1 (zh) 2002-05-24
JP2002522554A (ja) 2002-07-23
US6268207B1 (en) 2001-07-31
EP1105413A2 (en) 2001-06-13
US6420380B2 (en) 2002-07-16
JP2010043124A (ja) 2010-02-25
SK2062001A3 (en) 2001-10-08
HRP20010102A2 (en) 2002-02-28
IL141012A0 (en) 2002-02-10
EP1105413B1 (en) 2009-04-29
US6329379B1 (en) 2001-12-11
EE200100081A (et) 2002-08-15
EP2028186B1 (en) 2013-01-23
ES2405930T3 (es) 2013-06-04
CN101143892A (zh) 2008-03-19
HK1040085B (zh) 2008-05-30
DK1105413T3 (da) 2009-08-17
KR20060083992A (ko) 2006-07-21
CY1109291T1 (el) 2014-07-02
SA99200617A (ar) 2005-12-03
JP5021711B2 (ja) 2012-09-12
WO2000009543A2 (en) 2000-02-24
PL204850B1 (pl) 2010-02-26
PE20000949A1 (es) 2000-09-26
EA200100228A1 (ru) 2001-10-22
ID27839A (id) 2001-04-26
CA2338946C (en) 2010-10-12
WO2000009543A3 (en) 2000-05-25
HUP1300080A2 (forum.php) 2002-04-29
MXPA01001423A (es) 2001-08-01
AU5273199A (en) 2000-03-06
IL196545A0 (en) 2011-07-31
KR20010085363A (ko) 2001-09-07
KR100672229B1 (ko) 2007-02-28
EP2028186A3 (en) 2009-04-01
NZ510396A (en) 2004-02-27
CA2338946A1 (en) 2000-02-24

Similar Documents

Publication Publication Date Title
DK1105413T3 (da) Hepatitis C-inhibitor-tripeptider
DK1105422T3 (da) Hepatitis C-inhibitorpeptider
DK1004669T3 (da) Hidtil ukendte differentieringsinhibitor
PT1224195E (pt) C-aril-glicosidos inibidores de tgls2
DK0958287T3 (da) Sulfamidmetalloprotease-inhibitorer
DE19980536D2 (de) Vinylen- und Ethylverbindungen
NO20003256L (no) ACE inhibitor-MMP inhibitor kombinasjoner
DE69837922D1 (de) Il-5 hemmende 6-azauracilderivate
MA24838A1 (fr) Serre
DE19983684T1 (de) Befestigungsmittel
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
DE69903779D1 (de) Inhibitor- Schalter
DE69828361D1 (de) Apoptose-inhibitor
EP1007548A4 (en) THROMBIN INHIBITOR FROM TSE-TSE FLY
ID22727A (id) Senyawa ester
DK1012180T3 (da) Hepatitis C-inhibitorpeptidanaloger
NO980820L (no) Dusjhode
ITRA980008U1 (it) X
ITRA980006U1 (it) X
ITRA980004U1 (it) X
FI3607U1 (fi) Kiinnitin
FI3728U1 (fi) Kiinnityselin
FI3554U1 (fi) Teline